Precision opportunity DxTerity focuses on RNA-based immune profiling for autoimmune diseases, presenting a potential sales angle for reagents, sequencing services, and precision medicine platforms that could complement their diagnostic workflow and broaden their offerings to research partners and clinics.

Lupus collaboration Recent partnership with Lupus Research Alliance and a landmark five-year study signals ongoing collaboration opportunities with research networks, clinical sites, and patient advocacy groups that could benefit from scalable diagnostic and monitoring solutions.

SLE product access The launch of the IFN-1 Test for Systemic Lupus Erythematosus indicates readiness to commercialize targeted biomarkers; there is upside in offering complementary tests, data analytics, or integrated reporting to rheumatology practices and health systems.

Home and workplace testing Historical emphasis on at-home and employee-COVID screening demonstrates a capability and channel for remote diagnostics and employer programs; explore partnerships with employers, insurers, and telehealth platforms for autoimmune monitoring solutions.

Growth signals Revenue in the low to mid single-digit millions with a small team suggests high potential for scalable partnerships, channel partnerships, and OEM collaborations to expand distribution, leveraging existing tech stack and cloud-based workflows.